TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31694677

Group type: EXPERIMENTAL
Intervention: Image fusion group utilizing 3D preoperative planning and image fusion system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group utilizing only 3D preoperative planning
Number of subjects: 42
Study: 29486321

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 27831987

Group type: EXPERIMENTAL
Intervention: Predictive model for proximal junctional failure (PJF) or clinically significant proximal junctional kyphosis (PJK) based on demographic, radiographic, and surgical factors.
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Predictors included age, lower‐most instrumented vertebra (LIV), pre‐operative sagittal vertical axis (SVA), upper‐most instrumented vertebra (UIV) implant type, UIV, pre‐operative pelvic tilt (PT), and pre‐operative pelvic incidence minus lumbar lordosis (PI-LL).
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: PJF defined as requiring revision for PJK.
Number of subjects: 510
Study: 25179849

Group type: EXPERIMENTAL
Intervention: Early aggressive therapy
Number of subjects: 48
Study: 22870185

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 5098

Group type: EXPERIMENTAL
Intervention: Age and blood pressure
Number of subjects: 5098

Group type: COMPARATOR
Intervention: Fasting glucose and 2 h OGTT
Number of subjects: 5098
Study: 20331668

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study: 18026680

Group type: EXPERIMENTAL
Intervention: Shared Mental Health Care (IA)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control Area (CA)
Number of subjects: 709
Study: 16378115

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg administered before rebeat
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 20
Study: 11833860

Group type: EXPERIMENTAL
Intervention: 6 g sodium oxybate
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 9 g sodium oxybate
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 3 g sodium oxybate
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 10416249

Group type: EXPERIMENTAL
Intervention: Ozone (10, 100, 500, 1000 micrograms/m3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formaldehyde (5000 micrograms/m3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic air (control)
Number of subjects: 0
Study: 7737713

Group type: EXPERIMENTAL
Intervention: Addition of 25 mg hydrochlorothiazide once daily for 1 month
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderate reduction in salt intake (from 206 +/- 26 to 109 +/- 20 mmol urinary sodium/24 h) added to captopril for 1 month
Number of subjects: 11

Group type: COMPARATOR
Intervention: Addition of hydrochlorothiazide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Moderate reduction in salt intake
Number of subjects: 11
Study: 2149655

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 1168

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1168
Study: 6248010

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 31846600

Group type: EXPERIMENTAL
Intervention: Running red lights (always vs. never)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riding after drinking (yes vs. no)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carrying adults while riding (always vs. never)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Turning without signaling (sometimes vs. never)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riding in the motor vehicle lane (always vs. never)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior crash history (yes vs. no)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of e-bikes (scooter-style e-bikes vs. bicycle-style e-bikes)
Number of subjects: 0
Study: 29653532

Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention for psychosis, duration of 8 weeks, includes modules on delusion, voice hearing, social competence, mindfulness, and others.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group, duration of 8 weeks.
Number of subjects: 0
Study: 28805177

Group type: EXPERIMENTAL
Intervention: Fish protein isolate (FPi) diet
Number of subjects: 441

Group type: COMPARATOR
Intervention: Standard diet without FPi
Number of subjects: 441
Study: 26323291

Group type: EXPERIMENTAL
Intervention: Smoking (two cigarettes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (30-min waiting period)
Number of subjects: 0
Study: 24088993

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: HS + 6% dextran‐70 (HSD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: HS
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: HSD
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: HS, HSD
Number of subjects: 83
Study: 21958068

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg plus Telmisartan 80 mg
Number of subjects: 75
Study: 17996211

Group type: EXPERIMENTAL
Intervention: Deep lamellar endothelial keratoplasty (DLEK)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 27
Study: 16860426

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel (52.5mg, 3.5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12840628

Group type: EXPERIMENTAL
Intervention: Moderately active participants (4.5-7.4 weight-bearing h.d-1)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Most active participants (>=7.5 weight-bearing h.d-1)
Number of subjects: 400
Study: 10963811

Group type: EXPERIMENTAL
Intervention: Birch-pollen immunotherapy (IT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Birch-pollen extract (BPE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tetanus toxoid (TT)
Number of subjects: 25
Study: 8985103

Group type: EXPERIMENTAL
Intervention: Cold packs (Cryogel, 8-12 degrees C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hot packs (Parafango, 50-60 degrees C)
Number of subjects: 12
Study: 1728157

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 27
Study: 6371879

Group type: EXPERIMENTAL
Intervention: Trazodone (TZD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31335194

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1362
Study: 29352823

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Computer Game (CG)
Number of subjects: 56
Study: 26628552

Group type: EXPERIMENTAL
Intervention: Patient-centred bedside rounds (PCBR)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no PCBR)
Number of subjects: 236
Study: 25319597

Group type: EXPERIMENTAL
Intervention: Psychological intervention for DVA survivors
Number of subjects: 260

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 260
Study: 23243245

Group type: COMPARATOR
Intervention: AMP processed to particle size of 300 mum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AMP processed to particle size of 149 mum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AMP processed to particle size of 75 mum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AMP processed to particle size of 37 mum
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AMP (5 g/kg of diet)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basal diet only (control)
Number of subjects: 120
Study: 21308291

Group type: EXPERIMENTAL
Intervention: Subgingival instrumentation with ultrasonic device using PVP-I (10%) as cooling liquid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Identical treatment using distilled water as cooling liquid
Number of subjects: 32
Study: 17714828

Group type: EXPERIMENTAL
Intervention: Rapid ingestion of a large glucose beverage consumed with breakfast and lunch
Number of subjects: 14

Group type: COMPARATOR
Intervention: Slow ingestion of the same volume of glucose beverage consumed in eight portions
Number of subjects: 14
Study: 16368799

Group type: EXPERIMENTAL
Intervention: epoprostenol (3 ng x kg(‐1) x min(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 14564686

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d and MPA 2.5 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11697754

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Amlodipine (dosage not specified)
Number of subjects: 28
Study: 9395691

Group type: EXPERIMENTAL
Intervention: Active Enermed device (magnetically active)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo device (magnetically inactive)
Number of subjects: 30
Study: 7910272

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (group L) with transabdominal stapling of preperitoneal Prolene mesh.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Open hernia repair (group O) with tension-free nylon darn.
Number of subjects: 150
Study: 2853528

Group type: EXPERIMENTAL
Intervention: minus lenses with full correction for distant vision only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: bifocal lenses
Number of subjects: 240

Group type: COMPARATOR
Intervention: minus lenses with full correction for continuous use (Reference group)
Number of subjects: 240
Study: 31468553

Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 426
Study: 29141079

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg, single intravitreal injection)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 220
Study: 25957056

Group type: EXPERIMENTAL
Intervention: Intravenous lysine acetylsalicylate (LA) 450 mg plus oral prasugrel 60 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral aspirin 300 mg plus prasugrel 60 mg
Number of subjects: 30
Study: 22167660

Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21597295

Group type: EXPERIMENTAL
Intervention: Elevated plasma homocysteine levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal plasma homocysteine levels (control group implied)
Number of subjects: 0
Study: 19567309

Group type: EXPERIMENTAL
Intervention: Supplemental buccal and lingual infiltrations of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Supplemental buccal and lingual infiltrations of 4% articaine with 1:200,000 epinephrine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no supplemental infiltrations)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Comparison between 4% articaine and 2% lidocaine
Number of subjects: 84
Study: 16776681

Group type: EXPERIMENTAL
Intervention: Low-level lipopolysaccharide (LPS) 2 microg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19
Study: 15517755

Group type: EXPERIMENTAL
Intervention: 3M Cavilon No Sting Barrier Film (Cavilon NSBF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zinc oxide oil
Number of subjects: 40
Study: 11429350

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual sedation
Number of subjects: 0
Study: 9256139

Group type: EXPERIMENTAL
Intervention: CTVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days plus pirarubicin 50 mg/m2)
Number of subjects: 453

Group type: COMPARATOR
Intervention: CVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: CTVP
Number of subjects: 453

Group type: COMPARATOR
Intervention: CVP
Number of subjects: 453
Study: 8016565

Group type: EXPERIMENTAL
Intervention: Predeposit autologous blood transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untransfused patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfused with allogeneic blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfused with autologous blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfused with both types of blood
Number of subjects: 0
Study: 30279573

Group type: COMPARATOR
Intervention: miRs (specifically miRs-374b, -454, -142-3p, -191, -424, -590-3p, -29c, and -15b)
Number of subjects: 36
Study: 30392575

Group type: EXPERIMENTAL
Intervention: 3 daily capsules of 200 mg DHA each (n=176)
Number of subjects: 345

Group type: COMPARATOR
Intervention: 3 daily capsules of vegetable oil without DHA (n=169)
Number of subjects: 345
Study: 27109816

Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 12.5, 25 or 50 μg twice daily (BID) plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 25 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 50 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Beclometasone dipropionate plus formoterol fumarate (BDP/FF) alone
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 12.5 μg BID
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 25 μg BID
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Extrafine glycopyrronium bromide (GB) 50 μg BID
Number of subjects: 178
Study: 24495365

Group type: EXPERIMENTAL
Intervention: SMS appointment reminders (present)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No SMS appointment reminders (absent)
Number of subjects: 140
Study: 22215473

Group type: EXPERIMENTAL
Intervention: Reduced-dose RCHOP chemotherapy (375 mg/m² rituximab, 600 mg/m² cyclophosphamide, 30 mg/m² doxorubicin, 1 mg vincristine, and 40 mg prednisone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Reduced-dose RCHOP chemotherapy
Number of subjects: 85
Study: 20521870

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) initiated at 10 mg/day for opioid-naive patients and equianalgesic dose for opioid-experienced patients.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in patients aged <65 years.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in patients aged >=65 years.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in oxycodone-experienced patients.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) titration in hydrocodone-experienced patients.
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Successful titration of oxymorphone ER regardless of prior opioid therapy, sex, or age.
Number of subjects: 575
Study: 18208828

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-dose warfarin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-dose warfarin with aspirin
Number of subjects: 15
Study: 16135834

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg, single intravenous infusion)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Risedronate (30 mg per day for 60 days)
Number of subjects: 347
Study: 11812681

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine 0.2% (2 mg/kg)
Number of subjects: 20
Study: 10418698

Group type: EXPERIMENTAL
Intervention: Tryptophan-depleting (T-) amino acid mixture
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine hydrochloride (60 mg) after T-
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nutritionally balanced (B) amino acid mixture containing tryptophan
Number of subjects: 28
Study: 7572689

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 559
Study: 2115538

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 456

Group type: COMPARATOR
Intervention: Conservative management after thrombolysis
Number of subjects: 456
Study: 7428409

Group type: EXPERIMENTAL
Intervention: Controlled-release aminophylline plus routine inhaled salbutamol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Controlled-release aminophylline and inhaled salbutamol on demand
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Controlled-release aminophylline plus inhaled salbutamol on need
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral salbutamol plus routinely inhaled salbutamol
Number of subjects: 11
Study: 31032979

Group type: EXPERIMENTAL
Intervention: Skills 4 Life program (Social Emotional Learning program)
Number of subjects: 66
Study: 30080997

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Interval detection
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Nonscreened/postscreening
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Screen detected SCLC
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Interval detected SCLC
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Nonscreened/postscreening SCLC
Number of subjects: 143

Group type: COMPARATOR
Intervention: NSCLC cases
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: LDCT imaging
Number of subjects: 143
Study: 27372902

Group type: EXPERIMENTAL
Intervention: Alertness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (AC) training
Number of subjects: 0
Study: 25025610

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 10804

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10804
Study: 22372405

Group type: COMPARATOR
Intervention: Red wine and grape juice extracts (WGM) for 4 days
Number of subjects: 0
Study: 20588072

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study: 17199887

Group type: EXPERIMENTAL
Intervention: standard follow-up
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: nurse-led telephone follow-up
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: arm 1 with the educational group programme
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: arm 2 with the educational group programme
Number of subjects: 320
Study: 16373217

Group type: EXPERIMENTAL
Intervention: Mixed-methods evaluation of a rehabilitation scheme
Number of subjects: 6

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethnographic study
Number of subjects: 6
Study: 11943957

Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite combined with hypotonic oral rehydration solution (Gastrolit)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gastrolit alone (control group)
Number of subjects: 54
Study: 10848048

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 7791156

Group type: EXPERIMENTAL
Intervention: Criticism of the spouse
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Low number of friends
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Low level of potential support
Number of subjects: 229
Study: 2198696

Group type: EXPERIMENTAL
Intervention: Norcolut
Number of subjects: 434
Study: 832652

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 10
Study: 31599059

Group type: EXPERIMENTAL
Intervention: Topical 2% ketoconazole cream
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 41
Study: 30204683

Group type: EXPERIMENTAL
Intervention: Fat grafting (Group 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conservative management followed by fat grafting (Group 2)
Number of subjects: 31
Study: 27749549

Group type: EXPERIMENTAL
Intervention: Group G (mandibular angle approach)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group H (Hartel anterior approach)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group G
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group H
Number of subjects: 108
Study: 24424249

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 789

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Ranibizumab PRN (after 6 months of sham treatment)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Sham treatment followed by ranibizumab 0.5 mg PRN
Number of subjects: 789
Study: 22212377

Group type: EXPERIMENTAL
Intervention: PUFA 4 g daily for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48